Aquestive advances Anaphylm FDA resubmission after positive study results
Aquestive Therapeutics Inc. reported positive human factors and pharmacokinetic study results for its Anaphylm sublingual film, addressing prior FDA concerns regarding packaging and administration errors. The company plans to resubmit its New Drug Application in Q3 2026 while advancing global regulatory filings. Shares rose 13.45% on the news.
*this image is generated using AI for illustrative purposes only.
Aquestive Therapeutics Inc. (NASDAQ: AQST) has advanced its regulatory timeline for Anaphylm (dibutepinephrine), a sublingual film treatment for Type 1 allergic reactions including anaphylaxis, following successful human factors and pharmacokinetic validation studies. The positive data resolves key usability and safety concerns raised by the U.S. Food and Drug Administration (FDA) in a Complete Response Letter issued in January 2026, clearing the path for a planned New Drug Application (NDA) resubmission in the third quarter of 2026. This development reduces execution risk for the company’s lead asset and supports its broader commercial strategy across North America and Europe.
The studies were designed to address specific deficiencies identified in previous trials, where participants experienced difficulties opening packaging, tearing the film, incorrect placement, chewing, or premature removal. Aquestive implemented redesigned packaging, updated instructions, and modified labeling to mitigate these issues. The revised design demonstrated significant improvements across all identified metrics, directly responding to the regulatory feedback that had delayed the approval process.
Human Factors Study Improvements
The latest human factors study quantified the impact of the design changes on user performance. Key metrics showed substantial reductions in error rates and time-to-use compared to the previous trial.
| Metric | Previous Trial Result | Revised Trial Result |
|---|---|---|
| Median package opening time | 17 seconds | 3 seconds |
| Pouch opening difficulty | 26 out of 166 participants | 1 out of 105 participants |
| Improper placement | 20 participants | 2 participants |
| Chewing or premature removal | Occurred | Zero subjects |
These improvements indicate that the redesigned system significantly enhances the reliability of self-administration in emergency scenarios, a critical factor for FDA approval of anaphylaxis treatments.
Pharmacokinetic Results and Safety Profile
A single pharmacokinetic study compared self-administration against clinician-assisted and intramuscular administration methods. The study recorded zero errors during self-use, validating the efficacy of the new instructions and packaging. To further address regulatory requirements, Aquestive evaluated the performance impact of purposely misplaced film on top of the tongue or the roof of the mouth.
While misplaced administration lowered peak concentration and extended absorption time compared to correct placement, top-of-tongue administration still achieved robust pharmacodynamic effects. Specifically, it reached a geometric mean maximum concentration above 100 pg/mL with a median peak time of 35 minutes. These effects were comparable to or greater than those of injectable epinephrine. The study reported no serious adverse events or drug discontinuations, reinforcing the safety profile of the sublingual film.
What the Numbers Show
The reduction in median package opening time from 17 seconds to 3 seconds represents an 82% improvement in access speed, which is critical in anaphylaxis events where rapid intervention is life-saving. Furthermore, the drop in pouch opening difficulty from approximately 15.7% (26/166) to less than 1% (1/105) suggests that the primary barrier to effective use—user error in accessing the device—has been largely eliminated. The pharmacokinetic data confirms that even under suboptimal conditions (misplacement), the drug maintains therapeutic relevance, providing a safety net for users who may not achieve perfect placement during a crisis.
Commercial Resubmission Timeline
Aquestive remains on track to submit its NDA resubmission during the third quarter of 2026. Concurrently, the company is advancing regulatory applications in Canada, the United Kingdom, and the European Union, expanding its potential market reach beyond the U.S. Following the announcement, Aquestive Therapeutics shares rose 13.45% to $4.36 on Monday, reflecting investor confidence in the company’s ability to overcome regulatory hurdles and progress toward commercialization.
How might the successful resolution of human factors issues influence the FDA's review timeline for the Q3 2026 NDA resubmission compared to standard processing times?
What is Aquestive's strategy for differentiating Anaphylm's market positioning against established injectable epinephrine auto-injectors given the sublingual administration route?
How will the concurrent regulatory submissions in Canada, the UK, and the EU impact Aquestive's capital allocation and cash burn rate prior to potential commercialization?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
